SCHEMBL14764174

SCHEMBL14764174

CCOc1cc(C)ccc1[O]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.47
MAPT P10636 5/20 0.47
RAB9A P51151 1/20 0.47
ATM Q13315 1/20 0.47
POLB P06746 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
TSHR P16473 5/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
KDM4E B2RXH2 3/20 0.42
HSD17B10 Q99714 3/20 0.41
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 2/20 0.40
ACHE P22303 1/20 0.40
KCNMA1 Q12791 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14764344 0.83 MAPT (0.47) L3MBTL1MAPTRAB9AATMPOLB
SCHEMBL805356 0.80 MAPT (0.61) L3MBTL1MAPTRAB9AATMPOLB
SCHEMBL6766643 0.79 KDM4E (0.56) MAPTALDH1A1HPGDTDP1TSHR
SCHEMBL10190610 0.79 L3MBTL1 (0.50) L3MBTL1MAPTRAB9AATMPOLB
SCHEMBL148506 0.78 TSHR (0.55) L3MBTL1MAPTRAB9AATMPOLB
SCHEMBL14764249 0.78 MAPT (0.42) L3MBTL1MAPTPOLBALDH1A1HPGD
SCHEMBL8765719 0.77 TSHR (0.46) L3MBTL1MAPTRAB9AATMPOLB
SCHEMBL16954273 0.76 MAPT (0.45) L3MBTL1MAPTRAB9AATMPOLB
SCHEMBL1802754 0.76 ACHE (0.62) L3MBTL1MAPTRAB9APOLBALDH1A1
SCHEMBL6941203 0.75 MAPT (0.61) L3MBTL1MAPTRAB9AATMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190085007-A1 4-methylcatechol Derivatives and Uses Thereof Thanares GmbH (DE) 2019-03-21 US claimed
US-20160347782-A1 4-methylcatechol Derivatives and Uses Thereof Thanares GmbH (DE) 2016-12-01 US claimed
WO-2013034119-A1 4-METHYLCATECHOL DERIVATIVES UND USE THEREOF Thanares GmbH (DE) 2013-03-14 WO claimed
US-20190085007-A1 4-methylcatechol Derivatives and Uses Thereof Thanares GmbH (DE) 2019-03-21 US disclosed
US-20160347782-A1 4-methylcatechol Derivatives and Uses Thereof Thanares GmbH (DE) 2016-12-01 US disclosed
WO-2013034119-A1 4-METHYLCATECHOL DERIVATIVES UND USE THEREOF Thanares GmbH (DE) 2013-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190085007-A1 4-methylcatechol Derivatives and Uses Thereof ST3GAL3, GALE, DPP4 L3MBTL1 3349/4885MAPT 1067/4885RAB9A 3889/4885
US-20160347782-A1 4-methylcatechol Derivatives and Uses Thereof ST3GAL3, GALE, DPP4 L3MBTL1 3349/4885MAPT 1067/4885RAB9A 3889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.